GlassScriptPhysician profile
Jae-Koo An
NPI 1205805447
$2,358.38
in general payments reported to CMS, 2019-2025
17 companies · $371 in 2025
The $371 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $258 · 2021: $331 · 2022: $266 · 2023: $405 · 2024: $413 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,188.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $993.57 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Regeneron Healthcare Solutions, INC. | $536.53 | 2022-2025 | Dupixent |
| Genzyme Corporation | $347.45 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $128.37 | 2020-2025 | Eohilia |
| Qol Medical, LLC | $49.31 | 2019-2020 | |
| Amgen INC. | $48.21 | 2022-2023 | Avsola, Amjevita |
| Nestle Healthcare Nutrition INC. | $47.29 | 2021-2022 | |
| Concordia Pharmaceuticals INC. | $33.87 | 2019 | |
| Mirum Pharmaceuticals, INC. | $33.59 | 2024-2025 | Livmarli, Chenodal, Cholbam |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.40 | 2024 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $23.97 | 2024 | |
| Alcresta Therapeutics, INC. | $23.81 | 2024 | Relizorb |
| Aimmune Therapeutics, INC. | $23.61 | 2025 | Zenpep |
| Pharming Healthcare, INC. | $16.26 | 2025 | Ruconest |
| Covidien LP | $12.58 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $11.56 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3,623.30 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jae-Koo An listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.